First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks. Nicholas J A, Racke M K, Imitola J, Boster A L Ther Adv Chronic Dis. 2014 Mar; 5(2):62-68. PMID: 24587891. Abstract CommentRecommendBookmarkWatch